Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study

Autor: Abdullah F. Al Harthi, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Raghdah S. Alenezi, Shmeylan Al Harbi, Jawaher Gramish, Raed Kensara, Awattif Hafidh, Huda Al Enazi, Ahad Alawad, Rand Alotaibi, Abdulaziz Alshehri, Omar Alhuthaili, Ramesh Vishwakarma, Khalid bin Saleh, Thamer Alsulaiman, Rahaf Ali Alqahtani, Sajid Hussain, Saja Almazrou, Khalid Al Sulaiman
Rok vydání: 2022
Předmět:
Zdroj: Journal of Intensive Care Medicine. 37:1238-1249
ISSN: 1525-1489
0885-0666
Popis: Background Aspirin is widely used as a cardioprotective agent due to its antiplatelet and anti-inflammatory properties. The literature has assessed and evaluated its role in hospitalized COVID-19 patients. However, no data are available regarding its role in COVID-19 critically ill patients. This study aimed to evaluate the use of low-dose aspirin (81-100 mg) and its impact on outcomes in critically ill patients with COVID-19. Method A multicenter, retrospective cohort study of all critically ill adult patients with confirmed COVID-19 admitted to intensive care units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were classified into two groups based on aspirin use during ICU stay. The primary outcome was in-hospital mortality, and other outcomes were considered secondary. Propensity score matching was used (1:1 ratio) based on the selected criteria. Results A total of 1033 patients were eligible, and 352 patients were included after propensity score matching. The in-hospital mortality (HR 0.73 [0.56, 0.97], p = 0.03) was lower in patients who received aspirin during stay. Conversely, patients who received aspirin had a higher odds of major bleeding than those in the control group (OR 2.92 [0.91, 9.36], p = 0.07); however, this was not statistically significant. Additionally, subgroup analysis showed a possible mortality benefit for patients who used aspirin therapy prior to hospitalization and continued during ICU stay (HR 0.72 [0.52, 1.01], p = 0.05), but not with the new initiation of aspirin (HR 1.22 [0.68, 2.20], p = 0.50). Conclusion Continuation of aspirin therapy during ICU stay in critically ill patients with COVID-19 who were receiving it prior to ICU admission may have a mortality benefit; nevertheless, it may be associated with an increased risk of significant bleeding. Appropriate evaluation for safety versus benefits of utilizing aspirin therapy during ICU stay in COVID19 critically ill patients is highly recommended.
Databáze: OpenAIRE
Externí odkaz: